세계의 엑소좀 진단 및 치료 시장 규모 및 예측 : 용도별, 제품별, 최종사용자별, 지역별 분석(2023-2030년)

Global Exosome Diagnostic and Therapeutic Market is valued at approximately USD 375.64 million in 2022 and is anticipated to grow with a healthy growth rate of more than 29.4% over the forecast period 2023-2030. Exosome Diagnostic and Therapeutic refer to the use of exosomes, which are small membrane vesicles secreted by cells, for diagnostic and therapeutic purposes in various medical applications. Exosomes contain a variety of biomolecules, including proteins, nucleic acids (such as DNA, RNA, and microRNAs), lipids, and metabolites, which reflect the physiological and pathological status of their parent cells. Exosomes can serve as valuable biomarkers for the diagnosis and prognosis of various diseases. Since exosomes are released into bodily fluids like blood, urine, and saliva, they offer a non-invasive method for obtaining diagnostic information. The Exosome Diagnostic and Therapeutic market is expanding because of factors such as the increasing prevalence of chronic disease and a surge in demand for molecular diagnosis. As a result, the demand for Exosome Diagnostic and Therapeutic has progressively increased in the international market during the forecast period 2023-2030.

Chronic diseases often require early detection and continuous monitoring for effective management. Exosomes contain molecular signatures reflective of their cell of origin and carry biomolecules like proteins, nucleic acids, and lipids. By analyzing exosome content, clinicians can detect disease-specific biomarkers earlier than traditional methods, enabling timely intervention and monitoring of disease progression. According to the United Nations report, chronic diseases are anticipated to account for 70% of all global fatalities, while the global disease burden will be 56% by the year 2030. The most significant growth is expected in the African and Eastern Mediterranean regions. Furthermore, increasing understanding of exosome biology and its role in disease pathogenesis has spurred significant research and development efforts in the exosome diagnostic and therapeutic space. This includes the discovery of exosome biomarkers, the development of advanced isolation and detection techniques, and the exploration of exosome-based therapeutics. Another important factor that drives the Exosome Diagnostic and Therapeutic market is the increasing demand for molecular diagnosis. Molecular diagnosis allows for a more precise understanding of diseases at the molecular level, enabling personalized treatment strategies. Exosomes, tiny vesicles released by cells, carry valuable molecular information reflecting the status of the parent cells. By analyzing exosome contents, including proteins, nucleic acids, and lipids, molecular diagnosis facilitates the detection of specific biomarkers indicative of various diseases such as cancer, infectious diseases, and neurological disorders. In addition, as per Frontier Organization, exosomes derived from stem cells contain growth factors and signaling molecules that can stimulate cell proliferation and tissue healing. Exosome-based therapies are being explored for conditions like heart disease and tissue injuries. Moreover, the integration of advanced exosome technology in drug development and the increasing development of translational precision medicine is anticipated to create a lucrative growth opportunity for the market over the forecast period. However, the high development cost of exosome based therapeutic drugs and stringent government regulations towards drug approval are going to impede overall market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Exosome Diagnostic and Therapeutic Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the prevalence of chronic diseases in the region. According to the Centers for Disease Control and Prevention, 6 out of 10 Adults in the United States have a chronic disease. Chronic diseases often require early detection and continuous monitoring to manage effectively. Exosome-based diagnostics offer a non-invasive and sensitive method for early detection of diseases such as cancer, cardiovascular diseases, and neurological disorders. These diagnostics enable healthcare providers to intervene at earlier stages of the disease, leading to better outcomes for patients. The region's dominant performance is anticipated to propel the overall demand for Exosome Diagnostic and Therapeutic. Furthermore, Asia Pacific is expected to grow fastest during the forecast period, owing to factors such as growth in healthcare expenditures in the region. Higher healthcare spending often leads to the expansion and modernization of healthcare infrastructure, including hospitals, research facilities, and diagnostic laboratories. This expanded infrastructure can provide the necessary resources and facilities for the development, testing, and commercialization of exosome-based diagnostics and therapeutics.

Major market players included in this report are:

• Malvern Instruments Limited
• System Biosciences Incorporated
• Exiqon A/S
• Capricor Therapeutics, Inc.
• NanoSomix, Inc.
• Thermo Fisher Scientific Incorporated
• Sistemic Limited
• Exosome Diagnostic, Inc.
• NX Pharmagen, Inc.
• Aethlon Medical, Inc.

Recent Developments in the Market:

• In June 2023, Evox Therapeutics Ltd, a leading exosome therapeutics company, purchased Codiak Biosciences' engEx-AAV technology platform, including all intellectual property rights and exclusive access to certain engineering and manufacturing rights. This approach allows for active loading of adeno-associated virus into exosomes, followed by release when the AAV-loaded exosomes are transported to target cells. This is a successful method for improving AAV delivery, expanding the range of expression in pre-clinical rats, and protecting AAVs from neutralizing antibodies.

Global Exosome Diagnostic and Therapeutic Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Application, Product, End User, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent to up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters to detailed information about the crucial aspects such as driving factors & challenges that will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application

• Diagnostic
• Therapeutic

By Product

• Instrument
• Reagent
• Software

By End User

• Cancer Institute
• Hospital
• Diagnostic Center
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
  • 1.2.1.Exosome Diagnostic and Therapeutic Market, by Region, 2020-2030 (USD Million)
  • 1.2.2.Exosome Diagnostic and Therapeutic Market, by Application, 2020-2030 (USD Million)
  • 1.2.3.Exosome Diagnostic and Therapeutic Market, by Product, 2020-2030 (USD Million)
  • 1.2.4.Exosome Diagnostic and Therapeutic Market, by End User, 2020-2030 (USD Million)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Exosome Diagnostic and Therapeutic Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Exosome Diagnostic and Therapeutic Market Dynamics

• 3.1.Exosome Diagnostic and Therapeutic Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Increasing Prevalence of Chronic Disease
    • 3.1.1.2.Surge In Demand for Molecular Diagnosis
  • 3.1.2.Market Challenges
    • 3.1.2.1.High Development Cost of Exosome Based Therapeutic Drugs
    • 3.1.2.2.Stringent Government Regulations on Drug Approval
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Integration Of Advance Exosome Technology in Drug Development
    • 3.1.3.2.Increasing Development of Translational Precision Medicine

Chapter 4.Global Exosome Diagnostic and Therapeutic Market Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economical
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Exosome Diagnostic and Therapeutic Market, by Application

• 5.1.Market Snapshot
• 5.2.Global Exosome Diagnostic and Therapeutic Market by Application, Performance - Potential Analysis
• 5.3.Global Exosome Diagnostic and Therapeutic Market Estimates & Forecasts by Application 2020-2030 (USD Million)
• 5.4.Exosome Diagnostic and Therapeutic Market, Sub Segment Analysis
  • 5.4.1.Diagnostic
  • 5.4.2.Therapeutic

Chapter 6.Global Exosome Diagnostic and Therapeutic Market, by Product

• 6.1.Market Snapshot
• 6.2.Global Exosome Diagnostic and Therapeutic Market by Product, Performance - Potential Analysis
• 6.3.Global Exosome Diagnostic and Therapeutic Market Estimates & Forecasts by Product 2020-2030 (USD Million)
• 6.4.Exosome Diagnostic and Therapeutic Market, Sub Segment Analysis
  • 6.4.1.Instrument
  • 6.4.2.Reagent
  • 6.4.3.Software

Chapter 7.Global Exosome Diagnostic and Therapeutic Market, by End User

• 7.1.Market Snapshot
• 7.2.Global Exosome Diagnostic and Therapeutic Market by End User, Performance - Potential Analysis
• 7.3.Global Exosome Diagnostic and Therapeutic Market Estimates & Forecasts by End User 2020-2030 (USD Million)
• 7.4.Exosome Diagnostic and Therapeutic Market, Sub Segment Analysis
  • 7.4.1.Cancer Institute
  • 7.4.2.Hospital
  • 7.4.3.Diagnostic Center
  • 7.4.4.Others

Chapter 8.Global Exosome Diagnostic and Therapeutic Market, Regional Analysis

• 8.1.Top Leading Countries
• 8.2.Top Emerging Countries
• 8.3.Exosome Diagnostic and Therapeutic Market, Regional Market Snapshot
• 8.4.North America Exosome Diagnostic and Therapeutic Market
  • 8.4.1.U.S. Exosome Diagnostic and Therapeutic Market
    • 8.4.1.1.Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2.Product breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3.End User breakdown estimates & forecasts, 2020-2030
  • 8.4.2.Canada Exosome Diagnostic and Therapeutic Market
• 8.5.Europe Exosome Diagnostic and Therapeutic Market Snapshot
  • 8.5.1.U.K. Exosome Diagnostic and Therapeutic Market
  • 8.5.2.Germany Exosome Diagnostic and Therapeutic Market
  • 8.5.3.France Exosome Diagnostic and Therapeutic Market
  • 8.5.4.Spain Exosome Diagnostic and Therapeutic Market
  • 8.5.5.Italy Exosome Diagnostic and Therapeutic Market
  • 8.5.6.Rest of Europe Exosome Diagnostic and Therapeutic Market
• 8.6.Asia-Pacific Exosome Diagnostic and Therapeutic Market Snapshot
  • 8.6.1.China Exosome Diagnostic and Therapeutic Market
  • 8.6.2.India Exosome Diagnostic and Therapeutic Market
  • 8.6.3.Japan Exosome Diagnostic and Therapeutic Market
  • 8.6.4.Australia Exosome Diagnostic and Therapeutic Market
  • 8.6.5.South Korea Exosome Diagnostic and Therapeutic Market
  • 8.6.6.Rest of Asia Pacific Exosome Diagnostic and Therapeutic Market
• 8.7.Latin America Exosome Diagnostic and Therapeutic Market Snapshot
  • 8.7.1.Brazil Exosome Diagnostic and Therapeutic Market
  • 8.7.2.Mexico Exosome Diagnostic and Therapeutic Market
• 8.8.Middle East & Africa Exosome Diagnostic and Therapeutic Market
  • 8.8.1.Saudi Arabia Exosome Diagnostic and Therapeutic Market
  • 8.8.2.South Africa Exosome Diagnostic and Therapeutic Market
  • 8.8.3.Rest of Middle East & Africa Exosome Diagnostic and Therapeutic Market

Chapter 9.Competitive Intelligence

• 9.1.Key Company SWOT Analysis
• 9.2.Top Market Strategies
• 9.3.Company Profiles
  • 9.3.1.Malvern Instruments Limited
    • 9.3.1.1.Key Information
    • 9.3.1.2.Overview
    • 9.3.1.3.Financial (Subject to Data Availability)
    • 9.3.1.4.Product Summary
    • 9.3.1.5.Recent Developments
  • 9.3.2.System Biosciences Incorporated
  • 9.3.3.Exiqon A/S
  • 9.3.4.Capricor Therapeutics, Inc.
  • 9.3.5.NanoSomix, Inc.
  • 9.3.6.Thermo Fisher Scientific Incorporated
  • 9.3.7.Sistemic Limited
  • 9.3.8.Exosome Diagnostic, Inc.
  • 9.3.9.NX Pharmagen, Inc.
  • 9.3.10.Aethlon Medical, Inc

Chapter 10.Research Process

• 10.1.Research Process
  • 10.1.1.Data Mining
  • 10.1.2.Analysis
  • 10.1.3.Market Estimation
  • 10.1.4.Validation
  • 10.1.5.Publishing
• 10.2.Research Attributes
• 10.3.Research Assumption